Alzamend Neuro, Inc. balance sheet ALZN

Annual Quarterly

As of Jul 31, 2026, Alzamend Neuro, Inc. had total assets of $8.5 million and total liabilities of $2.7 million. Total assets were up 35.0% from a year earlier. Stockholders' equity was $5.8 million. Cash and investments were $7.6 million.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2027
Jul 31, 2026
FY 2026
Apr 30, 2026
FY 2025
Apr 30, 2025
FY 2024
Apr 30, 2024
FY 2023
Apr 30, 2023
FY 2022
Apr 30, 2022
FY 2021
Apr 30, 2021
Assets
Cash
8
+35.1%
1
-82.0%
4
+950.0%
0
-92.7%
5
-63.4%
14
+629.0%
2
Cash and investments
8
+35.1%
1
-82.0%
4
+950.0%
0
-92.7%
5
-63.4%
14
+629.0%
2
Total current assets
8
+39.2%
2
-57.8%
4
+817.6%
0
-92.2%
6
-59.5%
14
+394.9%
3
Property and equipment, net
0
-27.8%
0
-26.0%
0
+141.3%
0
+120.9%
0
-22.4%
0
—
Total assets
9
+35.0%
2
-54.8%
5
+628.8%
1
-89.3%
6
-59.2%
15
+398.4%
3
Liabilities and equity
Accounts payable
—
—
—
3
+1.9%
3
+146.8%
1
+130.9%
1
Total current liabilities
—
—
—
—
3
+146.4%
1
+29.5%
1
Total liabilities
3
+178.6%
1
+112.1%
1
-80.3%
3
+12.4%
3
+146.4%
1
—
Stockholders' equity
6
+8.6%
1
-81.5%
4
+253.0%
-3
-185.2%
3
-77.2%
13
+563.3%
2
Ratios
Current ratio
—
—
—
—
2.03x
12.37x
3.24x
Return on equity
-156.77%
-1,196.43%
-113.78%
—
-488.53%
-92.59%
-250.71%
Return on assets
-106.49%
-421.88%
-98.09%
-1,575.04%
-251.51%
-85.16%
-173.27%
Book value per share
1.20
0.17
5.10
-33.94
4.71
0.14
0.03
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ALZN (Nasdaq)
Fiscal year ends
April 30
Incorporated in
DE
Headquarters
Atlanta, GA
SEC filer status
, Emerging growth company
SEC CIK
1677077

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.